Early bone mineral density decrease is associated with FSH and LH, not estrogen.

BACKGROUND: It remains unclear whether gonadotropins or estrogen is responsible for early bone mineral density (BMD) decrease in Chinese women. METHODS: A cross-sectional study was conducted on 368 healthy adult women, aged 35-60 years. We measured BMD, calculated BMD decrease rates (BDRs) and assessed serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E(2)) levels. RESULTS: BDR was significantly negatively correlated with serum FSH (r=-0.429 to -0.622, all p=0.000) and LH (r=-0.359 to -0.526, all p=0.000). After adjustment for age and body mass index, the negative correlations of serum FSH and LH with BDR persisted, but there was no overall correlation between serum E(2) and BDR. Multiple linear stepwise regression analysis suggested that serum FSH is a negative determinant of BDR. Serum E(2) seems to be a positive determinant of BDR in a few parts of the skeleton. CONCLUSIONS: The decrease of BMD during the menopause is associated with FSH and LH levels, rather than E(2) in Chinese women.

Control of hypertension in rats using volatile components of leaves of Taxus chinensis var. mairei.

ETHNOPHARMACOLOGICAL RELEVANCE: The leaves of Taxus chinensis var. mairei (Taxaceae) is used traditionally to fill pillows in some rural areas of China. Its volatile substances have been speculated to be capable of improving sleep quality, making blood pressure stable, and having diuretic capacity as recorded in Ancient Chinese Materia Medica. Using animal models and new technologies, we confirmed the hypotensive potential of volatile components from leaves of Taxus chinensis var. mairei (VCLT). MATERIALS AND METHODS: VCLT was obtained by supercritical CO(2) extraction equipment from Taxus chinensis var. mairei fresh leaves. Hypertensive rats were pre-induced by intraperitoneal (i,p.) injection of Nω-Nitro-l-Ariginine (l-NNA) for 15 days (15mg/kg, twice a day), then divided into 5 groups and subjected to the following treatments. l-NNA group (group 1) receiving l-NNA alone (15mg/kg, i.p., twice per day for 6 weeks); in addition to receiving l-NNA same as group 1, Hydrochlorothiazide (HDZ) group (group 2) receiving HDZ (orally administration, 5mg/kg, once per day for 6 weeks); VCLT groups (groups 3-5), including VCLT1, VCLT2, VCLT3. The VCLT rats were housed in an enclosed cage (2 rats/0.064m(3)). VCLT was mixed well and sprayed on fresh leaves surface of Taxus chinensis var. mairei (100ml/kg) with three dosages: 167g/kg (VCLT1), 233g/kg (VCLT2) and 333g/kg (VCLT3), respectively. Systolic Blood Pressure (SBP), plasma nitric oxide (NO), plasma angiotensin II, postprandial blood glucose, fasting blood glucose and blood lipids were determined. RESULTS: VCLT prevented the increase of SBP and plasma angiotensin II in l-NNA treated rats. Although VCLT does not significantly reduce blood triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C), it decreases total cholesterol (TC) while increasing plasma NO levels in a dose-dependent manner. CONCLUSION: VCLT can be used as a natural and supplementary reagents for the treatment of hypertension.